Please ensure Javascript is enabled for purposes of website accessibility

Merck Announces a Big Planned Spinoff

By Jim Crumly – Feb 5, 2020 at 1:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma giant will form a new publicly traded company out of its women's health and biosimilars businesses, and its legacy brands.

Merck (MRK 0.18%) announced Wednesday its intention to spin off its women's health business,  legacy brands, and biosimilars unit into an independent, publicly traded company, and reorient itself toward its higher-growth businesses. The slimmed-down Merck will focus on oncology, vaccines, hospital products, and animal health.

The transaction is planned as a tax-free distribution of newly issued shares in the yet-to-be-named spinoff company. Merck expects to receive a tax-free payment of $8 billion to $9 billion from the new company ("NewCo") when the deal closes in the first half of 2021.

Cartoon of two people pulling apart a "company" sign.

Image source: Getty Images.

Merck believes that spinning off the slower-growing businesses will allow it to increase investments in its core growth areas and significantly expand its operating margin; management is targeting a non-GAAP operating margin of more than 40% by 2024, compared with the current level in the mid-30% range.  NewCo will have strong cash flows and growth opportunities in biosimilars, contraceptives, and fertility, as well as through the development of sales in foreign markets.

The pharmaceutical giant plans to maintain its current dividend of $2.44 per share after the spinoff, and expects that NewCo will pay a meaningful dividend that will be incremental to Merck's payout.

Investors may be concerned that this move makes Merck even more dependent on growth from its mega-blockbuster cancer immunotherapy Keytruda. Wall Street gave the announcement, which arrived along with the release of a mixed fourth-quarter earnings report, a cool reception. Shares were trading about 3% lower as of 1:30 p.m. EST.

Jim Crumly owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$87.60 (0.18%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.